(Rac)-Vazegepant-13C,d3
Product Specifications
UNSPSC Description
(Rac)-Vazegepant-13C,d3 is the C13 and deuterium labeled (Rac)-Vazegepant. Vazegepant (HY-134992) is the first intranasal CGRP receptor antagonist for the study the acute research of migraine[1][2].
Target Antigen
Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Others
Field of Research
Others
Solubility
10 mM in DMSO
Smiles
CC1=C2NN=CC2=CC(CC(NC(N3CCC(C4=CC5=CC=CC=C5NC4=O)CC3)=O)C(N6CCN(C7CCN([13C]([2H])([2H])[2H])CC7)CC6)=O)=C1
Molecular Weight
642.81
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]Leonard KA, et al. Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease. J Med Chem. 2020 Mar 26;63(6):2915-2929.
Shipping Conditions
Room temperature
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1369540-01 0.02 mg (E-Coli)
Recombinant Brucella suis biovar 1 Phosphatidylserine decarboxylase proenzyme (psd)
Ask
View Details MBS1369540-02 0.1 mg (E-Coli)
Recombinant Brucella suis biovar 1 Phosphatidylserine decarboxylase proenzyme (psd)
Ask
View Details